Evidence

Proven results published by top healthcare companies

The world’s largest healthcare companies use AdhereTech for tens of thousands of patients. These firms will only use technologies that are proven to be effective by the most reliable sources. That is why AdhereTech is especially proud to share results that have been published by similar large healthcare companies, for their actual patients in the real world. We’re especially proud that our results are consistent across different patient populations, pharmacies, medications, and disease states.

Weill Cornell

HIV Adherence Bottle Intervention Trial (HABIT):

“In a randomized study of diverse [HIV Patients] with suboptimal adherence, [AdhereTech] was associated with higher tenofovir diphosphate levels, a quantitative marker of adherence”

view clinical poster
  • All results proven via biological assay measuring medication levels in the blood
  • Patients using AdhereTech had optimal levels of medication in the blood “on the order of around one additional dose per week” vs patients not using AdhereTech
  • “Using an objective novel marker, intracellular tenofovir diphosphate by dried blood spot, demonstrates the best evidence of the use of [AdhereTech] to improve adherence.”
  • Conducted and published by Chief of Infectious Disease at Weill Cornell, Dr. Roy Gulick (Former Chairman of the FDA's Antiviral Drugs Advisory Committee)

Avella Specialty Pharmacy

UnitedHealth Group

“AdhereTech improves adherence and generates 1-2 additional fills of medication per patient per year, across multiple specialty medications and diseases”

view published report
  • "Averaged across all patients and programs… AdhereTech has improved duration on therapy by 26%, fill rates by 9%, and dose-level adherence by 15%."
  • "Patient feedback is overwhelmingly positive, with the average patient satisfaction rating at 4.7 out of 5."
  • "Avella currently uses the AdhereTech program for five specialty medications, in programs with four different pharmaceutical manufacturers."

US Bioservices

AmerisourceBergen

“Patients using AdhereTech Smart Pill Bottles through US Bioservices stayed on therapy longer, refilled prescriptions more frequently”

view published report
  • "Patients new to therapy who began treatment with the Smart Pill Bottle stayed on therapy for 1.5 additional months and had 1.3 additional fills dispensed."
  • "Consistently, patients continuing on a therapy had 1.2 additional fills dispensed compared to their peers not in the program."
  • "[AdhereTech] is directly correlated to more positive outcomes."

Diplomat Pharmacy

Largest Independant Pharmacy in the US

“The average patient using AdhereTech bottles experienced more than one additional medication fill [annually]”

view published report
  • "Over a year, the average patient using AdhereTech bottles experienced a 12 percent higher patient retention rate"
  • "19 fewer gap days [annually] (time without medication between fills)"
  • "Adherence and persistence improvements for patients using AdhereTech"

JMCP Peer-Reviewed Study

UnitedHealth Group

“AdhereTech patients had more consistent dosing behavior”

view journal article
  • “[AdhereTech] demonstrated a significantly higher median adherence of 100% compared with the control arm median adherence of 87.4% (P = 0.001)."
  • "In addition to improved adherence, [AdhereTech patients] completed more cycles”
  • “[AdhereTech patients] had more regulated behavior and took a greater proportion of doses during the optimal 2-hour dosing window (83% vs. 22%; P < 0.001)
  • ”[AdhereTech] patients reported high satisfaction levels of 4.7 out of 5 with 5 ‘strongly agree’ ratings for ease of set up and ease of use”
Most of the AdhereTech’s data reports are confidential, but some non-confidential reports can be shared with relevant parties, upon request.
Please contact us for more information.